Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy

Autor: Jonel Trebicka, Yasuko Iwakiri
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Cirrhosis
Dll4
delta like canonical Notch ligand 4
HRS
hepatorenal syndrome
PDE
phosphodiesterase
medicine.medical_treatment
Portal venous pressure
PIGF
placental growth factor
Hsp90
heat shock protein 90
AT1R
angiotensin II type I receptor
PKG
cGMP-dependent protein kinase
Review
HSC
MLCP
myosin light-chain phosphatase
Chronic liver disease
Bioinformatics
PDGF
platelet-derived growth factor
angiogenesis
Hepatorenal syndrome
NET
neutrophil extracellular trap
CCl4
carbon tetrachloride
Immunology and Allergy
JAK2
Janus kinase 2
Gastroenterology
eNOS
endothelial nitric oxide synthase
VEGF
VEGF
vascular endothelial growth factor
ECM
extracellular matrix
β1-AR
β1-adrenergic receptor
CCL2
chemokine (C-C motif) ligand 2
FXR
VCAM1
vascular cell adhesion molecule 1
Portal hypertension
NSBB
TIPS
Transjugular intrahepatic portosystemic shunt
EUS
endoscopic ultrasound
HSCs
hepatic stellate cells
NSBBs
non-selective beta blockers
NO
statins
FXR
farnesoid X receptor
TIPS
transjugular intrahepatic portosystemic shunt
Internal Medicine
medicine
ddc:610
LSEC
Rho-kinase
HVPG
hepatic venous pressure gradient
NO
nitric oxide
KO
knockout
Hepatology
business.industry
fibrosis
β2-AR
β2-adrenergic receptor
LSEC
liver sinusoidal endothelial cells
medicine.disease
Review article
liver stiffness
ACE2
angiogenesis-converting enzyme 2
CSPH
clinically significant portal hypertension
ACLF
acute-on-chronic liver failure
CLD
chronic liver disease
Hepatic stellate cell
β-Arr2
β-arrestin 2
business
HCC
hepatocellular carcinoma
Zdroj: JHEP Reports
JHEP reports 3(4), 100316 (2021). doi:10.1016/j.jhepr.2021.100316
DOI: 10.1016/j.jhepr.2021.100316
Popis: JHEP reports 3(4), 100316 (2021). doi:10.1016/j.jhepr.2021.100316
Published by Elsevier, Amsterdam
Databáze: OpenAIRE
Externí odkaz: